Pacific Biosciences of California, Inc. (PACB) stock forecast & analysis
2.39
NasdaqGS · USD
Up: +0.55, +30.3%
1 analysis
- Open
- 1.84
- Previous close
- 1.83
- Day range
- 1.84 – 2.46
- 52-week range
- 1.07 – 2.73
- Volume (shares)
- 63.43M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 310.83M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 2.31
- Market cap
- 741.33M
Market Scanner’s AI analysis of Pacific Biosciences of California, Inc. (PACB), updated September 2026: PacBio's recent reports covered significant price momentum alongside declining revenue and negative profitability.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Pacific Biosciences of California, Inc. (PACB) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
PacBio's recent reports covered significant price momentum alongside declining revenue and negative profitability.
Recent analyses for PacBio (PACB) examined a notable surge in stock price, with the shares trading well above key moving averages and showing strong short-term gains. This technical strength was accompanied by indicators of significant buying pressure. However, the fundamental picture revealed a year-over-year revenue decrease and continued negative net profit margins and return on equity.
PACB news & sentiment
News headlines indicated a positive trend for PacBio, highlighting stock price momentum and outperformance against market upswings. Some headlines also flagged the stock as making significant moves, suggesting notable investor interest.
PACB technical picture
PacBio's stock price showed strong recent momentum, trading significantly above its 50-day and 200-day Simple Moving Averages. Momentum indicators like the RSI, MFI, and MACD were elevated, suggesting substantial buying pressure, and the price was trading above the upper Bollinger Band.
Fundamentals
Revenue declined year-over-year in the latest reported quarter. Profitability metrics, including net profit margin and return on equity, remained negative over the trailing twelve months, though the net margin was higher than the operating margin.
Factors discussed — upside
- Stock price trading significantly above 50-day and 200-day SMAs
- Strong 7-day and 30-day price changes indicating uptrend
- High RSI and MFI suggesting strong buying pressure
- Positive MACD momentum
- Stock price trading above the upper Bollinger Band
Factors discussed — risks
- Latest quarter revenue decreased 1.9% year-over-year
- Trailing twelve months net profit margin is -82.5%
- Trailing twelve months Return on Equity is -929.3%
- Operating income for the latest quarter was -$44.61 million
- Net income for the latest quarter was -$44.741 million
- Technical momentum
- Revenue trends
- Profitability metrics
- Market sentiment
Summary updated .
PACB technical indicators
Common technical indicators for PACB, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.38 | Price above |
| 10-day exponential moving average | 1.71 | Price above |
| Relative strength index (14-day) | 84.77 | Overbought |
| MACD line (12/26/9) | 0.1506 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.95 – 1.98 | Price above the upper band |
Analyses
Recent PACB.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Pacific Biosciences of California, Inc.?
- Recent analyses highlighted significant stock price momentum, with shares trading well above key moving averages and showing strong short-term gains, supported by indicators of robust buying pressure and positive momentum.
- What are the risks for Pacific Biosciences of California, Inc.?
- The fundamental picture revealed a year-over-year revenue decrease and continued negative net profit margins and return on equity, alongside negative operating and net income figures for the latest quarter.
- Is Pacific Biosciences of California, Inc. bullish or bearish?
- Recent AI analyses of Pacific Biosciences of California, Inc. examined factors on both sides. Discussed upside: Recent analyses highlighted significant stock price momentum, with shares trading well above key moving averages and showing strong short-term gains, supported by indicators of robust buying pressure and positive momentum. Discussed risks: The fundamental picture revealed a year-over-year revenue decrease and continued negative net profit margins and return on equity, alongside negative operating and net income figures for the latest quarter. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Pacific Biosciences of California, Inc.?
- News headlines indicated a positive trend for PacBio, highlighting stock price momentum and outperformance against market upswings. Some headlines also flagged the stock as making significant moves, suggesting notable investor interest.
- How does Market Scanner analyse Pacific Biosciences of California, Inc.?
- Every analysis of Pacific Biosciences of California, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh PACB.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.